New drug cocktail aims to outsmart Treatment-Resistant melanoma
NCT ID NCT06594991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of three drugs—fianlimab, cemiplimab, and ipilimumab—can safely shrink tumors in people with advanced melanoma that no longer responds to standard PD-1 therapy. The study enrolls 88 adults with locally advanced or metastatic melanoma. Researchers will measure how many patients see their tumors shrink and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fianlimab, cemiplimab, and ipilimumab (drug combination)
What this could lead to
If successful, this could offer a new treatment option for people with advanced melanoma that no longer responds to standard immunotherapy.
What could go wrong
This is an early phase 2 trial with only 88 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-••••
-
Hackensack Meridian Health (Data Collection Only)
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-••••
-
Hartford Healthcare Alliance (Data Collection Only)
RECRUITINGHartford, Connecticut, 06102, United States
Contact Phone: •••-•••-••••
-
MD Anderson Cancer Center (Data Collection Only)
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Stanford University (Data Collection Only)
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-••••